albuterol has been researched along with Muscular Dystrophy, Duchenne in 4 studies
Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Muscular Dystrophy, Duchenne: An X-linked recessive muscle disease caused by an inability to synthesize DYSTROPHIN, which is involved with maintaining the integrity of the sarcolemma. Muscle fibers undergo a process that features degeneration and regeneration. Clinical manifestations include proximal weakness in the first few years of life, pseudohypertrophy, cardiomyopathy (see MYOCARDIAL DISEASES), and an increased incidence of impaired mentation. Becker muscular dystrophy is a closely related condition featuring a later onset of disease (usually adolescence) and a slowly progressive course. (Adams et al., Principles of Neurology, 6th ed, p1415)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fourteen boys with Duchenne or Becker muscular dystrophy, 6 to 11 years old, completed two treatment periods (albuterol and placebo), 12 weeks each, separated by a 12-week washout period." | 9.13 | Albuterol increases lean body mass in ambulatory boys with Duchenne or Becker muscular dystrophy. ( Fowler, EG; Graves, M; Skura, CL; Spencer, MJ; Wetzel, GT, 2008) |
| "Fourteen boys with Duchenne or Becker muscular dystrophy, 6 to 11 years old, completed two treatment periods (albuterol and placebo), 12 weeks each, separated by a 12-week washout period." | 5.13 | Albuterol increases lean body mass in ambulatory boys with Duchenne or Becker muscular dystrophy. ( Fowler, EG; Graves, M; Skura, CL; Spencer, MJ; Wetzel, GT, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fowler, EG | 2 |
| Graves, MC | 1 |
| Wetzel, GT | 2 |
| Spencer, MJ | 2 |
| Restrepo, S | 1 |
| Skura, CL | 1 |
| Graves, M | 1 |
| Lynch, GS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect on Body Composition With Albuterol and Caffeine Versus Placebo in Adolescents: A Pilot Study[NCT02740660] | 12 participants (Actual) | Interventional | 2016-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
DXA Scan of obese adolescents (NCT02740660)
Timeframe: Baseline, Week 8
| Intervention | kg (Mean) |
|---|---|
| Caffeine 100mg / Albuterol 4mg | 0.97 |
| Placebo | -0.21 |
DXA Scan of obese adolescents (NCT02740660)
Timeframe: Baseline, Week 8
| Intervention | kg (Mean) |
|---|---|
| Caffeine 100mg / Albuterol 4mg | 1.34 |
| Placebo | 0.88 |
(NCT02740660)
Timeframe: Baseline, Week 8
| Intervention | kg (Mean) |
|---|---|
| Caffeine 100mg / Albuterol 4mg | 2.57 |
| Placebo | 1.05 |
(NCT02740660)
Timeframe: Week 2, Week 4, Week 6, Week 8
| Intervention | Participants (Count of Participants) |
|---|---|
| Caffeine 100mg / Albuterol 4mg | 5 |
| Placebo | 2 |
1 review available for albuterol and Muscular Dystrophy, Duchenne
| Article | Year |
|---|---|
Therapies for improving muscle function in neuromuscular disorders.
Topics: Adjuvants, Immunologic; Adrenergic beta-Agonists; Albuterol; Aminoglycosides; Animals; Anti-Bacteria | 2001 |
2 trials available for albuterol and Muscular Dystrophy, Duchenne
| Article | Year |
|---|---|
Pilot trial of albuterol in Duchenne and Becker muscular dystrophy.
Topics: Adrenergic beta-Agonists; Albuterol; Child; Cross-Over Studies; Double-Blind Method; Dystrophin; Fol | 2004 |
Albuterol increases lean body mass in ambulatory boys with Duchenne or Becker muscular dystrophy.
Topics: Adrenergic beta-Agonists; Albuterol; Body Mass Index; Child; Double-Blind Method; Humans; Male; Musc | 2008 |
1 other study available for albuterol and Muscular Dystrophy, Duchenne
| Article | Year |
|---|---|
New treatment alternatives for Duchenne and Becker muscular dystrophy.
Topics: Administration, Oral; Adrenergic beta-Agonists; Albuterol; Child; Child, Preschool; Clinical Trials | 2004 |